메뉴 건너뛰기




Volumn 16, Issue 22, 2010, Pages 5499-5510

Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE; CASPASE 3; CASPASE 9; CYTARABINE; HISTONE H2AX; PROTEIN BCL 2; SHORT HAIRPIN RNA; VALPROIC ACID;

EID: 78349242181     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1707     Document Type: Article
Times cited : (74)

References (39)
  • 1
    • 34147145338 scopus 로고    scopus 로고
    • Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia
    • Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007;12:341-55.
    • (2007) Oncologist , vol.12 , pp. 341-355
    • Meshinchi, S.1    Arceci, R.J.2
  • 2
    • 36349018880 scopus 로고    scopus 로고
    • Pediatric acute myeloid leukemia: Towards high-quality cure of all patients
    • Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007;92: 1519-32.
    • (2007) Haematologica , vol.92 , pp. 1519-1532
    • Kaspers, G.J.1    Zwaan, C.M.2
  • 3
    • 8344272920 scopus 로고    scopus 로고
    • Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia
    • Zwaan CM, Kaspers GJ. Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. Br J Haematol 2004;127: 264-79.
    • (2004) Br J Haematol , vol.127 , pp. 264-279
    • Zwaan, C.M.1    Kaspers, G.J.2
  • 4
    • 0031972535 scopus 로고    scopus 로고
    • Ara-C: Cellular and molecular pharmacology
    • Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res 1998;72:197-233.
    • (1998) Adv Cancer Res , vol.72 , pp. 197-233
    • Grant, S.1
  • 6
    • 41949111045 scopus 로고    scopus 로고
    • Acute promyelocytic leukemia: From highly fatal to highly curable
    • Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15.
    • (2008) Blood , vol.111 , pp. 2505-2515
    • Wang, Z.Y.1    Chen, Z.2
  • 7
    • 34447507691 scopus 로고    scopus 로고
    • Targeting transcription factors in acute leukemia in children
    • Berman JN, Look AT. Targeting transcription factors in acute leukemia in children. Curr Drug Targets 2007;8:727-37.
    • (2007) Curr Drug Targets , vol.8 , pp. 727-737
    • Berman, J.N.1    Look, A.T.2
  • 8
    • 30344433284 scopus 로고    scopus 로고
    • Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress
    • Gao N, Rahmani M, Shi X, Dent P, Grant S. Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress. Blood 2006;107:241-9.
    • (2006) Blood , vol.107 , pp. 241-249
    • Gao, N.1    Rahmani, M.2    Shi, X.3    Dent, P.4    Grant, S.5
  • 9
    • 33748427812 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?
    • Gaymes TJ, Padua RA, Pla M, et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 2006;4:563-73.
    • (2006) Mol Cancer Res , vol.4 , pp. 563-573
    • Gaymes, T.J.1    Padua, R.A.2    Pla, M.3
  • 10
    • 51649126841 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
    • Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14:4500-10.
    • (2008) Clin Cancer Res , vol.14 , pp. 4500-4510
    • Ellis, L.1    Pan, Y.2    Smyth, G.K.3
  • 11
    • 21244464349 scopus 로고    scopus 로고
    • Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    • Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
    • (2005) J Clin Oncol , vol.23 , pp. 3923-3931
    • Kelly, W.K.1    O'Connor, O.A.2    Krug, L.M.3
  • 12
    • 4444309863 scopus 로고    scopus 로고
    • Treatment of myelodysplastic syndromes with valproic acid alone or in combination with alltrans retinoic acid
    • Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with alltrans retinoic acid. Blood 2004;104:1266-9.
    • (2004) Blood , vol.104 , pp. 1266-1269
    • Kuendgen, A.1    Strupp, C.2    Aivado, M.3
  • 13
    • 33748997409 scopus 로고    scopus 로고
    • Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia
    • Cimino G, Lo-Coco F, Fenu S, et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006;66:8903-11.
    • (2006) Cancer Res , vol.66 , pp. 8903-8911
    • Cimino, G.1    Lo-Coco, F.2    Fenu, S.3
  • 14
    • 33750530675 scopus 로고    scopus 로고
    • Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
    • Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-9.
    • (2006) Blood , vol.108 , pp. 3271-3279
    • Garcia-Manero, G.1    Kantarjian, H.M.2    Sanchez-Gonzalez, B.3
  • 15
    • 34948845116 scopus 로고    scopus 로고
    • Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
    • Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-8.
    • (2007) Blood , vol.110 , pp. 2302-2308
    • Soriano, A.O.1    Yang, H.2    Faderl, S.3
  • 16
    • 34249937594 scopus 로고    scopus 로고
    • Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: A clinical and translational study
    • Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-85.
    • (2007) J Clin Oncol , vol.25 , pp. 1979-1985
    • Munster, P.1    Marchion, D.2    Bicaku, E.3
  • 17
    • 18244383806 scopus 로고    scopus 로고
    • Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
    • Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78.
    • (2001) EMBO J , vol.20 , pp. 6969-6978
    • Gottlicher, M.1    Minucci, S.2    Zhu, P.3
  • 19
    • 3142692649 scopus 로고    scopus 로고
    • Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1
    • Tang R, Faussat AM, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004;18:1246-51.
    • (2004) Leukemia , vol.18 , pp. 1246-1251
    • Tang, R.1    Faussat, A.M.2    Majdak, P.3
  • 20
    • 13444274622 scopus 로고    scopus 로고
    • Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
    • Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-6.
    • (2005) Nat Med , vol.11 , pp. 71-76
    • Insinga, A.1    Monestiroli, S.2    Ronzoni, S.3
  • 21
    • 33747203758 scopus 로고    scopus 로고
    • Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
    • Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108:1174-82.
    • (2006) Blood , vol.108 , pp. 1174-1182
    • Sanchez-Gonzalez, B.1    Yang, H.2    Bueso-Ramos, C.3
  • 22
    • 20344394418 scopus 로고    scopus 로고
    • Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid
    • Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 2005;29:739-48.
    • (2005) Leuk Res , vol.29 , pp. 739-748
    • Yang, H.1    Hoshino, K.2    Sanchez-Gonzalez, B.3    Kantarjian, H.4    Garcia-Manero, G.5
  • 23
    • 33846502110 scopus 로고    scopus 로고
    • The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells
    • ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007;21:248-52.
    • (2007) Leukemia , vol.21 , pp. 248-252
    • Ten Cate, B.1    Samplonius, D.F.2    Bijma, T.3    De Leij, L.F.4    Helfrich, W.5    Bremer, E.6
  • 24
    • 34347375499 scopus 로고    scopus 로고
    • NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
    • Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007; 110:267-77.
    • (2007) Blood , vol.110 , pp. 267-277
    • Miller, C.P.1    Ban, K.2    Dujka, M.E.3
  • 25
    • 24744438875 scopus 로고    scopus 로고
    • Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27 (Kip 1) in acute myeloblastic leukemia cells
    • Siitonen T, Koistinen P, Savolainen ER. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27 (Kip 1) in acute myeloblastic leukemia cells. Leuk Res 2005;29: 1335-42.
    • (2005) Leuk Res , vol.29 , pp. 1335-1342
    • Siitonen, T.1    Koistinen, P.2    Savolainen, E.R.3
  • 26
    • 0033566994 scopus 로고    scopus 로고
    • Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin
    • Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999;94:1393-400.
    • (1999) Blood , vol.94 , pp. 1393-1400
    • Taub, J.W.1    Huang, X.2    Matherly, L.H.3
  • 27
    • 0034889197 scopus 로고    scopus 로고
    • Drug synergism: Its detection and applications
    • Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001;298:865-72.
    • (2001) J Pharmacol Exp Ther , vol.298 , pp. 865-872
    • Tallarida, R.J.1
  • 28
    • 33748794547 scopus 로고    scopus 로고
    • Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
    • Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
    • (2006) Pharmacol Rev , vol.58 , pp. 621-681
    • Chou, T.C.1
  • 29
    • 70350506780 scopus 로고    scopus 로고
    • RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: Role in chemotherapy sensitivity in acute megakaryocytic leukemia
    • Edwards H, Xie C, LaFiura KM, et al. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 2009;114:2744-52.
    • (2009) Blood , vol.114 , pp. 2744-2752
    • Edwards, H.1    Xie, C.2    LaFiura, K.M.3
  • 30
    • 13744252262 scopus 로고    scopus 로고
    • GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia
    • Ge Y, Stout ML, Tatman DA, et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 2005;97:226-31.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 226-231
    • Ge, Y.1    Stout, M.L.2    Tatman, D.A.3
  • 32
    • 0343280013 scopus 로고    scopus 로고
    • A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
    • Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
    • (2000) Curr Biol , vol.10 , pp. 886-895
    • Paull, T.T.1    Rogakou, E.P.2    Yamazaki, V.3    Kirchgessner, C.U.4    Gellert, M.5    Bonner, W.M.6
  • 33
    • 71949117093 scopus 로고    scopus 로고
    • Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: Evidence for distinct roles for Bcl-2, Bcl-xL, Mcl-1
    • Chen S, Dai Y, Pei XY, Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, Mcl-1. Mol Cell Biol 2009;29:6149-69.
    • (2009) Mol Cell Biol , vol.29 , pp. 6149-6169
    • Chen, S.1    Dai, Y.2    Pei, X.Y.3    Grant, S.4
  • 34
    • 27644556419 scopus 로고    scopus 로고
    • Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim
    • Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 2005;102:16090-5.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 16090-16095
    • Zhao, Y.1    Tan, J.2    Zhuang, L.3    Jiang, X.4    Liu, E.T.5    Yu, Q.6
  • 35
    • 0036201888 scopus 로고    scopus 로고
    • Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways
    • Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 2002; 26:495-502.
    • (2002) Leuk Res , vol.26 , pp. 495-502
    • Kawagoe, R.1    Kawagoe, H.2    Sano, K.3
  • 36
    • 29744454120 scopus 로고    scopus 로고
    • The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
    • Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106:112-9.
    • (2006) Cancer , vol.106 , pp. 112-119
    • Kuendgen, A.1    Schmid, M.2    Schlenk, R.3
  • 37
    • 33750454091 scopus 로고    scopus 로고
    • Oral rapid loading of valproic acid - An alternative to the usual saturation scheme?
    • Gerstner T, Bell N, Longin E, Konig SA. Oral rapid loading of valproic acid - an alternative to the usual saturation scheme? Seizure 2006; 15:630-2.
    • (2006) Seizure , vol.15 , pp. 630-632
    • Gerstner, T.1    Bell, N.2    Longin, E.3    Konig, S.A.4
  • 38
    • 0347628818 scopus 로고    scopus 로고
    • p21Waf1/Cip1 as a therapeutic target in breast and other cancers
    • Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-9.
    • (2003) Cancer Cell , vol.4 , pp. 425-429
    • Weiss, R.H.1
  • 39
    • 26244438834 scopus 로고    scopus 로고
    • BCL-2: Found bound and drugged!
    • Letai A. BCL-2: found bound and drugged! Trends Mol Med 2005; 11:442-4.
    • (2005) Trends Mol Med , vol.11 , pp. 442-444
    • Letai, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.